Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports ‘significant benefits’ of Actilyse

Boehringer Ingelheim reports ‘significant benefits’ of Actilyse

26th September 2008

Boehringer Ingelheim has announced the results of new research showing the benefits of Actilyse (alteplase) in patients with acute ischaemic stroke beyond the three-hour treatment window currently approved by regulators.

The results from the European Cooperative Acute Stroke Study were presented at the World Stroke Congress held in Vienna, Austria and published in the New England Journal of Medicine.

Boehringer Ingelheim said the safety profile of the recombinant tissue plasminogen activator when used in the three to four-and-a-half time window is consistent with that reported in previous trials for zero to three hours.

This safety profile includes the incidence of haemorrhagic events.

Professor Werner Hacke of the Department of Neurology at Ruprecht-Karls-University of Heidelberg, Germany, said: “The results of the trial show that a large group of patients currently excluded may benefit in the future from this therapy.”

He added while early treatment is the foundation of therapy for acute stroke treatments, the new study data shows stroke can also be effectively managed in patients unable to reach a stroke centre within three hours.

Earlier this week, Boehringer Ingelheim and Pfizer released the results of a new analysis of trials showing the long-term safety profile of Spiriva (tiotropium).

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.